Developer docs
API playgroundTry for free, no card

Search company profiles

DigestAID

Full company profile

uuid00093md

Namestring
DigestAID
Legal namestring
DIGESTAID – Artificial Intelligence Development, Lda.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

DigestAID (legal entity: DIGESTAID – Artificial Intelligence Development, Lda.) is a Porto, Portugal-based private medical-device company that develops AI-powered software for the detection and classification of lesions across the digestive and pancreatobiliary tracts. Founded in 2019, the company has built a portfolio of nine products organized into three clusters: capsule endoscopy (Deep Capsule, GI Spy, IBD Smart), AI live vision for cholangioscopy, endoscopic ultrasound, high-resolution anoscopy and device-assisted enteroscopy (Smart Cholangio, Smart Pancreas, Anoscopy Genius, Deep Bowel), and digestive motility analytics (Smart Mano, Smart Esophagus). All products are built on custom-designed Convolutional Neural Networks trained on a corpus of more than 2 million exams from world-renowned institutions, with reported diagnostic accuracy above 90% and over 100,000 exams processed in deployment.

The underlying platform processes video (up to 50,000 frames per capsule study), images, and structured manometry data through tailor-made CNNs that classify lesions and prioritize them by severity, with external cloud servers providing compute. DigestAID claims multi-brand device compatibility across the installed base of endoscopy equipment and holds eight patent applications, including a granted 20-year DeepCapsule patent, supported by 200+ peer-reviewed publications and multiple ACG Presidential Poster Awards. Clinical validation partnerships with the University of South Alabama, Hospital Universitario Puerta del Hierro, and the World Gastroenterology Organization anchor the evidence base, with the Medical R&D Chairman also serving as WGO President.

Commercially, DigestAID operates a B2B enterprise field-sales motion selling AI software subscriptions to gastroenterology practices, hospitals, GI endoscopy centers, and hepatopancreatobiliary specialists, with quote-based pricing, annual billing, and IFU-documented medical-device positioning. Pricing is not publicly disclosed, no funding rounds or revenue figures are reported, and the company appears to be in a clinical-validation and pre-commercial clearance phase while expanding its international footprint into Spain, Brazil, and the United States.

Short descriptiontext

DigestAID is a Porto-based AI medical-device company that builds deep learning software for lesion detection across the digestive and pancreatobiliary tracts, serving gastroenterology hospitals, endoscopy centers, and hepatopancreatobiliary specialists through enterprise sales.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPorto, Portugal
HQ citystring
Porto
HQ countrystring
Portugal
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI endoscopy solutions, capsule endoscopy analysis, gastroenterology AI software, medical imaging AI, lesion detection software
Industry4 codes
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLACAGAA
Diagnostic & Triage Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAKAEAC
Advanced Endoscopy (ERCP/EUS/Interventional)
SECONDARYHLAKAEAD
Inflammatory Bowel Disease (IBD) Care
NAICS code2 codes
  • Computer Systems Design and Related Services54151
  • Medical Laboratories621511
SIC code2 codes
  • Services-Prepackaged Software7372
  • Surgical & Medical Instruments & Apparatus3841
Product category
Gastroenterology AI Diagnostic Software
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1AI Software Licensing
TypeSubscription Recurring
Description

The company appears to license its AI software technology to healthcare institutions. Products like Deep Capsule have Instructions for Use (IFU) documents, suggesting regulatory-approved medical device software sales.

digestaid.health
2Clinical Validation Services
TypeProfessional Services
Description

Partnerships with healthcare institutions for technology validation and development, suggesting service-based revenue components.

digestaid.health
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise healthcare institutions - custom pricing
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing through contact/sales inquiry. Products are medical devices requiring regulatory approval.

digestaid.health
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

DigestAID develops AI-powered medical device software for digestive healthcare, applying custom-designed Convolutional Neural Networks to automatically detect and classify lesions during endoscopic procedures. Its portfolio spans capsule endoscopy, cholangioscopy, endoscopic ultrasound, high-resolution anoscopy, device-assisted enteroscopy, and anorectal/esophageal manometry. The products serve gastroenterologists and hospitals by prioritizing urgent findings, reducing manual review time, and improving diagnostic accuracy above 90%.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Global diagnostic accuracy >90% across AI solutions
+3 more records
Product overview1 text field

DigestAID is a portfolio of AI-powered medical devices and software solutions for digestive healthcare, organized into three main technology clusters. The Capsule Endoscopy cluster includes Deep Capsule (small bowel), GI Spy (panendoscopic colon capsule), and IBD Smart (Crohn's disease detection). The AI Live Vision cluster covers cholangioscopy (Smart Cholangio), endoscopic ultrasound (Smart Pancreas), anoscopy (Anoscopy Genius), and device-assisted enteroscopy (Deep Bowel). The Digestive Motility cluster includes Smart Mano (anorectal manometry) and Smart Esophagus (esophageal manometry). All products utilize proprietary deep learning convolutional neural networks for automatic lesion detection and classification, with external cloud servers providing computing power.

Product and service1 record
1Deep Capsule
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-13
Description

Global collaboration with University of South Alabama and Dr. Jack Di Palma (Master and Past President of American College of Gastroenterology) to develop and validate capsule endoscopy technologies for transformative software development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-11
Description

International collaboration for SmartCyst and SmartCholangio technologies. Dr. Belen Agudo Castillo and Dr. Mariano González-Haba Ruiz presented studies on pancreatic cystic lesions and biliary strictures using DigestAID technology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with WGO, whose President Guilherme Macedo serves as DigestAID's Medical R&D Chairman. Strategic alignment for advancing digestive healthcare globally.

4iCARE Group (International Capsule Endoscopy Research)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CEO Miguel Mascarenhas invited to join Scientific Committee of iCARE Group, a global leader shaping technological advancements in capsule endoscopy. Group fosters clinical and technological research through scientific collaborations.

digestaid.health
5Centro Hospitalar Universitário São João / Faculdade de Medicina da Universidade do Porto
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Precision Medicine Unit collaboration for Masterclass in Precision Medicine events, advancing AI and big data in digestive healthcare through patient-centered tailored medicine initiatives.

digestaid.health
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnerships providing over 2 million exams for algorithm training. Extensive and heterogeneous dataset from institutions worldwide enabling robust AI model development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Medtronic's GI Genius is the most widely deployed AI module for colonoscopy polyp detection, directly competing with DigestAID's capsule and AI Live Vision products in gastroenterology departments. As a multi-hundred-billion-dollar medtech incumbent with an installed colonoscopy base, Medtronic has the regulatory clearances and commercial channels that DigestAID lacks.

TypeDirect peer
Description

Iterative Health develops AI tools for GI endoscopy with a focus on inflammatory bowel disease and colonoscopy polyp detection, including the SKOUT and ScopeAI products. It is one of the closest direct competitors to DigestAID's IBD Smart and Deep Capsule, operating in the same gastroenterology AI category with similar B2B hospital GTM.

TypeDirect peer
Description

Magentiq Eye is an Israeli AI medical device company whose MAGENTIQ-COLO product automatically detects and characterizes polyps during colonoscopy, overlapping directly with DigestAID's colonoscopy-focused AI offerings. Both companies target gastroenterology departments with real-time lesion detection software.

TypeDirect peer
Description

Virgo builds AI-driven video capture, analysis, and quality improvement tools for endoscopy and surgical procedures, including GI indications. Its cloud-native platform overlaps with DigestAID's computer vision and severity-prioritization capabilities for endoscopy workflows.

TypeDirect peer
Description

Odin Vision is a UK-based AI endoscopy startup developing polyp detection and characterization software (Odin Art) for colonoscopy and upper GI procedures. It is a near-direct competitor to DigestAID's lesion detection products and was acquired by Olympus in 2023, illustrating incumbent bundling risk.

TypeBroad incumbent
Description

Olympus is the global leader in endoscopy hardware and has been aggressively expanding into AI through internal development (EndoBRAIN) and acquisitions (Odin Vision, Satisfai Health). Its installed base of endoscopes in hospitals worldwide makes it both a potential channel partner and the principal long-term competitive threat to DigestAID.

TypeBroad incumbent
Description

Fujifilm's endoscopy business (formerly Hitachi's) supplies a large share of GI endoscopy systems globally and is integrating AI-based lesion detection into its processors. Its CAD EYE platform competes head-to-head with DigestAID in colonoscopy AI-assisted detection.

TypeBroad incumbent
Description

Pentax Medical (Hoya Group) supplies flexible endoscopy systems used widely in gastroenterology and is investing in AI decision support features. It represents one of the three dominant endoscope incumbents whose installed-base advantage shapes hospital AI purchasing decisions relevant to DigestAID.

TypeEmerging player
Description

RSIP Vision is an Israeli AI company providing computer vision algorithms for medical imaging including endoscopy, colonoscopy, and pathology. While broader in scope than DigestAID, it operates in the same algorithmic-interpretation niche and supplies AI modules to medical device OEMs, potentially competing for the same hospital software budgets.

TypeEmerging player
Description

Motilent is a UK-based medical imaging AI company focused on gastrointestinal motility analysis (GIQuant for MRI). It overlaps with DigestAID's motility cluster (Smart Mano, Smart Esophagus) and represents a focused emerging competitor in the AI motility diagnostic space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DigestAID

Gastroenterology AI Diagnostic Softwaredigestaid.health

DigestAID is a Porto-based AI medical-device company that builds deep learning software for lesion detection across the digestive and pancreatobiliary tracts, serving gastroenterology hospitals, endoscopy centers, and hepatopancreatobiliary specialists through enterprise sales.

What DigestAID does

DigestAID (legal entity: DIGESTAID – Artificial Intelligence Development, Lda.) is a Porto, Portugal-based private medical-device company that develops AI-powered software for the detection and classification of lesions across the digestive and pancreatobiliary tracts. Founded in 2019, the company has built a portfolio of nine products organized into three clusters: capsule endoscopy (Deep Capsule, GI Spy, IBD Smart), AI live vision for cholangioscopy, endoscopic ultrasound, high-resolution anoscopy and device-assisted enteroscopy (Smart Cholangio, Smart Pancreas, Anoscopy Genius, Deep Bowel), and digestive motility analytics (Smart Mano, Smart Esophagus). All products are built on custom-designed Convolutional Neural Networks trained on a corpus of more than 2 million exams from world-renowned institutions, with reported diagnostic accuracy above 90% and over 100,000 exams processed in deployment.

The underlying platform processes video (up to 50,000 frames per capsule study), images, and structured manometry data through tailor-made CNNs that classify lesions and prioritize them by severity, with external cloud servers providing compute. DigestAID claims multi-brand device compatibility across the installed base of endoscopy equipment and holds eight patent applications, including a granted 20-year DeepCapsule patent, supported by 200+ peer-reviewed publications and multiple ACG Presidential Poster Awards. Clinical validation partnerships with the University of South Alabama, Hospital Universitario Puerta del Hierro, and the World Gastroenterology Organization anchor the evidence base, with the Medical R&D Chairman also serving as WGO President.

Commercially, DigestAID operates a B2B enterprise field-sales motion selling AI software subscriptions to gastroenterology practices, hospitals, GI endoscopy centers, and hepatopancreatobiliary specialists, with quote-based pricing, annual billing, and IFU-documented medical-device positioning. Pricing is not publicly disclosed, no funding rounds or revenue figures are reported, and the company appears to be in a clinical-validation and pre-commercial clearance phase while expanding its international footprint into Spain, Brazil, and the United States.

DigestAID firmographics

Firmographics
Name
DigestAID
Legal name
DIGESTAID – Artificial Intelligence Development, Lda.
Website
https://digestaid.health
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
DigestAID is a Porto-based AI medical-device company that builds deep learning software for lesion detection across the digestive and pancreatobiliary tracts, serving gastroenterology hospitals, endoscopy centers, and hepatopancreatobiliary specialists through enterprise sales.
Ownership category
akta.pro rank

DigestAID industry classification

Industry
Product category
Gastroenterology AI Diagnostic Software
NAICS
Computer Systems Design and Related Services (54151), Medical Laboratories (621511)
SIC
Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLACAGAA
Diagnostic & Triage Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
SECONDARYHLAKAEAC
Advanced Endoscopy (ERCP/EUS/Interventional)
SECONDARYHLAKAEAD
Inflammatory Bowel Disease (IBD) Care

Keywords

  • AI endoscopy solutions
  • Capsule endoscopy analysis
  • Gastroenterology AI software
  • Medical imaging AI
  • Lesion detection software

Where DigestAID is headquartered

Location

Headquarters

HQ city
Porto
HQ country
Portugal
HQ region
Europe

Offices1 record

Markets served

DigestAID business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. AI Software Licensing: The company appears to license its AI software technology to healthcare institutions. Products like Deep Capsule have Instructions for Use (IFU) documents, suggesting regulatory-approved medical device software sales.
  2. Clinical Validation Services: Partnerships with healthcare institutions for technology validation and development, suggesting service-based revenue components.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise healthcare institutions - custom pricing

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

DigestAID product offering

Product offering

Core offering

DigestAID develops AI-powered medical device software for digestive healthcare, applying custom-designed Convolutional Neural Networks to automatically detect and classify lesions during endoscopic procedures. Its portfolio spans capsule endoscopy, cholangioscopy, endoscopic ultrasound, high-resolution anoscopy, device-assisted enteroscopy, and anorectal/esophageal manometry. The products serve gastroenterologists and hospitals by prioritizing urgent findings, reducing manual review time, and improving diagnostic accuracy above 90%.

Product overview

DigestAID is a portfolio of AI-powered medical devices and software solutions for digestive healthcare, organized into three main technology clusters. The Capsule Endoscopy cluster includes Deep Capsule (small bowel), GI Spy (panendoscopic colon capsule), and IBD Smart (Crohn's disease detection). The AI Live Vision cluster covers cholangioscopy (Smart Cholangio), endoscopic ultrasound (Smart Pancreas), anoscopy (Anoscopy Genius), and device-assisted enteroscopy (Deep Bowel). The Digestive Motility cluster includes Smart Mano (anorectal manometry) and Smart Esophagus (esophageal manometry). All products utilize proprietary deep learning convolutional neural networks for automatic lesion detection and classification, with external cloud servers providing computing power.

Differentiator

Problem solved

Functional benefit

Products and services

  • Deep Capsule

Quantifiable outcome

  • Global diagnostic accuracy >90% across AI solutions
  • +3 more outcomes

Companies that use DigestAID

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles1 record

DigestAID technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

DigestAID partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • University of South AlabamacoreStrategic or Co-development Partner · 13 December 2023Global collaboration with University of South Alabama and Dr. Jack Di Palma (Master and Past President of American College of Gastroenterology) to develop and validate capsule endoscopy technologies for transformative software development.
  • Hospital Universitario Puerta del HierrocoreStrategic or Co-development Partner · 11 November 2023International collaboration for SmartCyst and SmartCholangio technologies. Dr. Belen Agudo Castillo and Dr. Mariano González-Haba Ruiz presented studies on pancreatic cystic lesions and biliary strictures using DigestAID technology.
  • World Gastroenterology Organization (WGO)coreStrategic or Co-development PartnerPartnership with WGO, whose President Guilherme Macedo serves as DigestAID's Medical R&D Chairman. Strategic alignment for advancing digestive healthcare globally.
  • iCARE Group (International Capsule Endoscopy Research)coreStrategic or Co-development PartnerCEO Miguel Mascarenhas invited to join Scientific Committee of iCARE Group, a global leader shaping technological advancements in capsule endoscopy. Group fosters clinical and technological research through scientific collaborations.
  • Centro Hospitalar Universitário São João / Faculdade de Medicina da Universidade do PortocoreStrategic or Co-development PartnerPrecision Medicine Unit collaboration for Masterclass in Precision Medicine events, advancing AI and big data in digestive healthcare through patient-centered tailored medicine initiatives.
  • World-renowned healthcare institutions (data partners)coreStrategic or Co-development PartnerPartnerships providing over 2 million exams for algorithm training. Extensive and heterogeneous dataset from institutions worldwide enabling robust AI model development.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

DigestAID competitors and assessment

Company assessment

Broad incumbents

  • Medtronic (GI Genius): Medtronic's GI Genius is the most widely deployed AI module for colonoscopy polyp detection, directly competing with DigestAID's capsule and AI Live Vision products in gastroenterology departments. As a multi-hundred-billion-dollar medtech incumbent with an installed colonoscopy base, Medtronic has the regulatory clearances and commercial channels that DigestAID lacks.
  • Olympus Corporation: Olympus is the global leader in endoscopy hardware and has been aggressively expanding into AI through internal development (EndoBRAIN) and acquisitions (Odin Vision, Satisfai Health). Its installed base of endoscopes in hospitals worldwide makes it both a potential channel partner and the principal long-term competitive threat to DigestAID.
  • Fujifilm Healthcare: Fujifilm's endoscopy business (formerly Hitachi's) supplies a large share of GI endoscopy systems globally and is integrating AI-based lesion detection into its processors. Its CAD EYE platform competes head-to-head with DigestAID in colonoscopy AI-assisted detection.
  • Pentax Medical (Hoya): Pentax Medical (Hoya Group) supplies flexible endoscopy systems used widely in gastroenterology and is investing in AI decision support features. It represents one of the three dominant endoscope incumbents whose installed-base advantage shapes hospital AI purchasing decisions relevant to DigestAID.

Direct peers

  • Iterative Health: Iterative Health develops AI tools for GI endoscopy with a focus on inflammatory bowel disease and colonoscopy polyp detection, including the SKOUT and ScopeAI products. It is one of the closest direct competitors to DigestAID's IBD Smart and Deep Capsule, operating in the same gastroenterology AI category with similar B2B hospital GTM.
  • Magentiq Eye: Magentiq Eye is an Israeli AI medical device company whose MAGENTIQ-COLO product automatically detects and characterizes polyps during colonoscopy, overlapping directly with DigestAID's colonoscopy-focused AI offerings. Both companies target gastroenterology departments with real-time lesion detection software.
  • Virgo Surgical Video Solutions: Virgo builds AI-driven video capture, analysis, and quality improvement tools for endoscopy and surgical procedures, including GI indications. Its cloud-native platform overlaps with DigestAID's computer vision and severity-prioritization capabilities for endoscopy workflows.
  • Odin Vision: Odin Vision is a UK-based AI endoscopy startup developing polyp detection and characterization software (Odin Art) for colonoscopy and upper GI procedures. It is a near-direct competitor to DigestAID's lesion detection products and was acquired by Olympus in 2023, illustrating incumbent bundling risk.

Emerging players

  • RSIP Vision: RSIP Vision is an Israeli AI company providing computer vision algorithms for medical imaging including endoscopy, colonoscopy, and pathology. While broader in scope than DigestAID, it operates in the same algorithmic-interpretation niche and supplies AI modules to medical device OEMs, potentially competing for the same hospital software budgets.
  • Motilent: Motilent is a UK-based medical imaging AI company focused on gastrointestinal motility analysis (GIQuant for MRI). It overlaps with DigestAID's motility cluster (Smart Mano, Smart Esophagus) and represents a focused emerging competitor in the AI motility diagnostic space.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

DigestAID social profiles

Digital presence

DigestAID compliance and trust

Trust signal

Compliance1 record

DigestAID financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DigestAID leadership team

Management profile

Number of profiles

Profiles12 records

DigestAID funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DigestAID M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DigestAID

What does DigestAID do?

DigestAID develops AI-powered medical device software for digestive healthcare, applying custom-designed Convolutional Neural Networks to automatically detect and classify lesions during endoscopic procedures. Its portfolio spans capsule endoscopy, cholangioscopy, endoscopic ultrasound, high-resolution anoscopy, device-assisted enteroscopy, and anorectal/esophageal manometry. The products serve gastroenterologists and hospitals by prioritizing urgent findings, reducing manual review time, and improving diagnostic accuracy above 90%.

Is DigestAID a public or private company?

DigestAID is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was DigestAID founded?

DigestAID was founded in 2019. It employs 11 to 50 people.

Where is DigestAID based?

DigestAID is headquartered in Porto, Portugal, in the Europe region.

How does DigestAID make money?

Two revenue lines are on record. AI Software Licensing is the primary driver. The others are clinical Validation Services.

Who are DigestAID's main competitors?

Broad incumbents on record are Medtronic (GI Genius), Olympus Corporation, Fujifilm Healthcare and Pentax Medical (Hoya). Direct peers are Iterative Health, Magentiq Eye, Virgo Surgical Video Solutions and Odin Vision. Emerging players are RSIP Vision and Motilent.

Does DigestAID have an API?

No public API is recorded for DigestAID.

What industry is DigestAID in?

DigestAID's product category is Gastroenterology AI Diagnostic Software. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HLACAGAA, Diagnostic & Triage Decision Support. Its NAICS code is 54151 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals